Tell me more about: CAR-T therapy details (specific product, infusion dates, acute toxicities)

CAR-T Therapy Information from Marlo's Records

Based on my review of the documents you've uploaded, I need to be direct with you: The current records do not contain detailed CAR-T therapy information such as specific product names, infusion dates, or acute toxicity data.

What the Documents DO Show About CAR-T:

In "Marlo's Treatment & Research Strategy - Working Document," CAR-T is discussed as a future consideration, not a completed treatment:

Current CAR-T Discussion Points:

• St. Jude 3CAR / B7-H3 CAR-T Trial is mentioned as a potential option to explore
• The document notes concerns about CAR-T efficacy in "cold" tumor environments (tumors with limited immune cell infiltration)
• There's a strategic question about timing: whether CAR-T should be used early or after "immune-priming" strategies (like a neoantigen vaccine)
• The document asks: "Could peptide vaccine or ADC 'prime' tumor for CAR-T?"

Action Items Listed (Not Yet Completed):

• Contact St. Jude trial coordinators
• Confirm trial enrollment status and eligibility criteria
• Discuss sequencing of CAR-T relative to other therapies

---

What This Means:

Based on these records, CAR-T appears to be in the planning/evaluation phase rather than an already-administered treatment. The team is strategically considering whether and when CAR-T might fit into Marlo's overall treatment plan.

---

Questions to Ask Your Care Team:

1. Has CAR-T therapy been administered, or is it still being evaluated? If administered, what product was used and when?
2. What were the specific reasons for choosing (or not choosing) CAR-T at this point in treatment?
3. If CAR-T is planned, what is the timeline, and would other therapies be given first to "prime" the tumor?
4. What are the specific eligibility criteria for the St. Jude B7-H3 CAR-T trial, and is Marlo a candidate?
5. What toxicity monitoring plan would be in place if CAR-T is pursued?

---

Why This Matters for Spindle Cell Sarcoma:

According to treatment strategy documents in your records, the team is thoughtfully considering the tumor microenvironment (the immune cells and proteins surrounding the cancer). Spindle cell sarcomas can sometimes be "cold" tumors—meaning they don't naturally attract many immune cells. This is why the strategy document explores "immune-priming" approaches (like neoantigen vaccines) before CAR-T, to potentially make the tumor more responsive to cell therapy.

---

If you have more recent records about CAR-T administration or if infusion dates and toxicity data exist in documents I haven't fully reviewed, please let me know and I can provide more specific details.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.